Predictors of successful outcome after adrenalectomy for unilateral primary aldosteronism.
adrenalectomy
hypertension
prediction systems
primary aldosteronism
resistant hypertension
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2023
2023
Historique:
received:
14
04
2023
accepted:
18
07
2023
medline:
29
8
2023
pubmed:
28
8
2023
entrez:
28
8
2023
Statut:
epublish
Résumé
Unilateral primary aldosteronism (UPA) is the most frequent surgically curable form of endocrine hypertension. Adrenalectomy is the cornerstone of treatment for UPA, but outcomes after surgery are variable. The cause of resistant hypertension after surgery is still a matter of debate. Our aim was to investigate cure rates after surgery and to evaluate preoperative factors that might influence the surgical outcome. Between 2000 and 2021, the charts of 71 Tunisian patients who underwent laparoscopic adrenalectomy for UPA were retrospectively reviewed. Preoperative medical records were collected and follow-up data (1-158 months) were registered. Antihypertensive medication doses were calculated using defined daily doses (DDD) and postoperative outcomes were assessed using the Primary Aldosteronism Surgical Outcome (PASO) criterion. Of 91 enrolled patients, 71 (59% women, mean age 46 years, median length of follow-up 21 months) were suitable for evaluation. Thirty-four patients (48%) had complete clinical success according to the PASO criteria. The most relevant factors associated with complete clinical success on univariate analysis were: absence of diabetes (p= 0.007), low body mass index (BMI) (p= 0.001), lower preoperative DDD (p= 0.01), preoperatively controlled blood pressure (p= 0.024), higher plasma aldosterone to renin ratio (ARR) (p= 0.001), adenoma subtyping (p <0.001) and aldosteronoma resolution score (ARS) (p= 0.002). Multivariate regression analysis showed that the major predictors of complete clinical success were absence of diabetes (OR: 5.205), a BMI < 30 (OR: 4.930), a plasma ARR > 332 (OR: 4.554) and an ARS ≥ 3 (OR: 2.056). Complete and partial clinical response rates were achieved in respectively 48 and 43% of cases. The main predictors of complete resolution of hypertension were absence of diabetes, low BMI, high plasma ARR and high ARS. Taking these factors into account may help identify patients at risk of persistent postoperative hypertension who may require long-term surveillance and medication.
Identifiants
pubmed: 37635962
doi: 10.3389/fendo.2023.1205988
pmc: PMC10454906
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1205988Informations de copyright
Copyright © 2023 Saadi, Bedoui, Zaghbib, Boussaffa, Mokaddem, Nacef, Ayed, Derouiche, Khiari, Chakroun and Ben Slama.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Clin Endocrinol Metab. 2008 Jul;93(7):2566-71
pubmed: 18445663
Lancet Diabetes Endocrinol. 2017 Sep;5(9):689-699
pubmed: 28576687
J Clin Endocrinol Metab. 2016 May;101(5):1889-916
pubmed: 26934393
World J Surg. 2018 Feb;42(2):453-463
pubmed: 29134312
Arch Intern Med. 2008 Jan 14;168(1):80-5
pubmed: 18195199
Ann Intern Med. 2009 Sep 1;151(5):329-37
pubmed: 19721021
Front Endocrinol (Lausanne). 2022 Aug 18;13:925591
pubmed: 36060937
Ann Surg. 2008 Mar;247(3):511-8
pubmed: 18376197
J Lab Clin Med. 1955 Apr;45(4):661-4
pubmed: 14368032
Hypertension. 2013 Aug;62(2):331-6
pubmed: 23753408
J Clin Hypertens (Greenwich). 2016 Dec;18(12):1205-1212
pubmed: 27759187
Br J Surg. 2002 Dec;89(12):1587-93
pubmed: 12445071
Int Surg. 2012 Apr-Jun;97(2):104-11
pubmed: 23102075
Arch Surg. 1996 Jun;131(6):646-50
pubmed: 8645073
Lancet. 2008 Jun 7;371(9628):1921-6
pubmed: 18539224
Horm Metab Res. 2012 Mar;44(3):157-62
pubmed: 22135219
Lancet Diabetes Endocrinol. 2016 Sep;4(9):739-746
pubmed: 27325147
J Am Coll Cardiol. 2006 Dec 5;48(11):2293-300
pubmed: 17161262
Horm Metab Res. 2012 Mar;44(3):221-7
pubmed: 22395801
Ann Surg. 2020 Dec;272(6):1125-1132
pubmed: 30672800
Hypertension. 2006 Aug;48(2):232-8
pubmed: 16801482
Surgery. 1998 Dec;124(6):1128-33
pubmed: 9854594
Int J Hypertens. 2011;2011:232683
pubmed: 21876786
Surgery. 2014 Dec;156(6):1394-402; discussion1402-3
pubmed: 25456918
J Clin Endocrinol Metab. 2020 Dec 1;105(12):
pubmed: 32898224
Clin Endocrinol (Oxf). 2021 Oct;95(4):576-586
pubmed: 34042196
Surgery. 2012 Mar;151(3):437-43
pubmed: 22000827
Cell Metab. 2013 Jan 8;17(1):20-33
pubmed: 23312281